Latest News and Press Releases

First patient dosed and study open in leading oncology centers in US and AustraliaPhase I/IIA adaptive study aims to assess and optimize the dose of OTP-01 and provide safety, tolerability, and early...

BRISBANE, Australia and CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Vaxxas Pty Ltd today announced the appointment of global biopharmaceutical executive Mr David Peacock as Chief Executive...

BGB Group strengthens pharma commercialization capabilities by integrating Hayden's payer and reimbursement expertise into its advisory practice.

CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...

U.S. JPML has created a new multidistrict litigation for lawsuits alleging that GLP-1 receptor agonist drugs cause NAION, a serious vision injury.

Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner’s Program Size Positions it to Become a Top Five...

Halo Pharma is expanding its manufacturing capabilities with the addition of a Gerteis Macro-Pactor at its Whippany, NJ, facility.

CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...

BRISBANE, Australia and CAMBRIDGE, Mass., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Australian biotechnology pioneer Vaxxas Pty Ltd, has been granted a licence by the Therapeutic Goods Administration...

The global market for brain tumor therapeutics was valued at $2.5 billion in 2024 and is projected to reach $4.7 billion by the end of 2030.